ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme
ITM
Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech
company, and Helmholtz Munich (Helmholtz Zentrum München), have announced a
cooperation agreement for the clinical development of a radiopharmaceutical
therapy candidate to treat malignant brain tumor glioblastoma. ITM and
Helmholtz Munich will collaborate to support an upcoming dose-escalation Phase
I clinical trial with LuCaFab (ITM-31). LuCaFab is a CA XII-specific antibody
Fab fragment targeting molecule, developed by Helmholtz Munich, radiolabeled
with ITM’s medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu,
EndolucinBeta®). The planned multicenter investigator-initiated trial (IIT)
will be led by the Westfälische Wilhelms-Universität Münster (University of Münster,
Germany).
Under
the terms of the agreement, which formalizes an ongoing collaboration between
ITM and Helmholtz Munich, ITM supports the logistics and supply of the clinical
trial material and provides funding for the trial, which is designed for the
treatment of up to 15 patients. ITM holds the exclusive option, which may be
executed at any time, to license the compound using related worldwide patents
and know-how for the manufacturing, use and application of LuCaFab from
Helmholtz Munich under the already agreed-upon
terms. The option also allows ITM to access and use trial data for research and
commercial activities.
To
read more please visit:
Source: ITM